This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Sep 19;318(11):1070-1071.

doi: 10.1001/jama.2017.11327.

Low-Dose Desmopressin Nasal Spray and FDA Approval

Seymour Fein¹, Samuel Herschkowitz¹

Affiliations

PMID: 28975296
DOI: 10.1001/jama.2017.11327

Comment

Low-Dose Desmopressin Nasal Spray and FDA Approval

Seymour Fein et al. JAMA. 2017.

. 2017 Sep 19;318(11):1070-1071.

doi: 10.1001/jama.2017.11327.

Authors

Seymour Fein¹, Samuel Herschkowitz¹

Affiliation

¹ Serenity Pharmaceuticals, Milford, Pennsylvania.

PMID: 28975296
DOI: 10.1001/jama.2017.11327

No abstract available

PubMed Disclaimer

Comment in

Low-Dose Desmopressin Nasal Spray and FDA Approval-Reply.
Fralick M, Kesselheim AS. Fralick M, et al. JAMA. 2017 Sep 19;318(11):1071-1072. doi: 10.1001/jama.2017.11343. JAMA. 2017. PMID: 28975301 No abstract available.

Comment on

FDA Approval of Desmopressin for Nocturia.
Fralick M, Kesselheim AS. Fralick M, et al. JAMA. 2017 May 23;317(20):2059-2060. doi: 10.1001/jama.2017.4316. JAMA. 2017. PMID: 28384655 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations